ENTITY

PegBio (2565 HK)

36
Analysis
Health Care • China
PegBio Co., Ltd. is a biotechnology company focused on the discovery and development of innovative therapies for chronic diseases, particularly metabolic disorders. The company develops differentiated therapeutics for conditions such as type 2 diabetes mellitus, obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. PegBio was founded in 2008 and is headquartered in Hangzhou, Zhejiang Province, China.
more
•28 May 2026 10:00

HK IPO Essential Statistics: Quantifying Lock-Up Expiry Overhang

HK IPO Essential Stat: We studied 43 HK IPO cornerstone deals listed in 2025 to quantify the selling pressure upon lock-up expiry.

Logo
203 Views
Share
•24 May 2026 10:05

HK Connect Flows Weekly (May 22nd): Alibaba, China Life, China Mobile, PICC P&C, SMIC, Tencent

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, China Life, China Mobile, PICC P&C, SMIC,...

Logo
135 Views
Share
•15 Apr 2026 10:30

HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't

HK Connect Mar 2026 implementation cycle is completing. ADD reversed the WAI drawdown at implementation. DELETE continuation worked post...

Logo
268 Views
Share
•20 Feb 2026 01:05

HK Connect March 2026: Implementation Forecast and Positioning Framework

March Connect implementation is nearing: we forecast expected ADD/DELETE actions and assess how positioning, crowding, and southbound flows may...

Logo
535 Views
Share
bullish•HashKey
•05 Jan 2026 05:50

HSCI Index Rebalance Preview and Stock Connect (Mar 2026): Many Changes Following Huge IPO Quarter

There could be 74 changes for the HSCI in March. That could result in 64 changes to the Southbound Stock Connect list and also have implications...

Logo
1.5k Views
Share
x